KR20090113478A - 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는프로바이오틱 유산균 락토바실러스 플란타늄 - Google Patents
항비만 및 뇌기능개선 관련 생리활성 기능을 가지는프로바이오틱 유산균 락토바실러스 플란타늄 Download PDFInfo
- Publication number
- KR20090113478A KR20090113478A KR1020080039216A KR20080039216A KR20090113478A KR 20090113478 A KR20090113478 A KR 20090113478A KR 1020080039216 A KR1020080039216 A KR 1020080039216A KR 20080039216 A KR20080039216 A KR 20080039216A KR 20090113478 A KR20090113478 A KR 20090113478A
- Authority
- KR
- South Korea
- Prior art keywords
- lactobacillus plantarum
- lactobacillus
- strain
- lactic acid
- group
- Prior art date
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 21
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 20
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 20
- 230000003925 brain function Effects 0.000 title description 8
- 230000000694 effects Effects 0.000 title description 5
- 239000006041 probiotic Substances 0.000 title description 3
- 230000000529 probiotic effect Effects 0.000 title description 3
- 235000018291 probiotics Nutrition 0.000 title description 3
- 230000003579 anti-obesity Effects 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 18
- 102000004877 Insulin Human genes 0.000 claims abstract description 9
- 108090001061 Insulin Proteins 0.000 claims abstract description 9
- 102000016267 Leptin Human genes 0.000 claims abstract description 9
- 108010092277 Leptin Proteins 0.000 claims abstract description 9
- 229940125396 insulin Drugs 0.000 claims abstract description 9
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims abstract description 9
- 229940039781 leptin Drugs 0.000 claims abstract description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 13
- 229960004203 carnitine Drugs 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 210000004185 liver Anatomy 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 6
- 230000006993 memory improvement Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 44
- 241000894006 Bacteria Species 0.000 abstract description 23
- 235000014655 lactic acid Nutrition 0.000 abstract description 22
- 239000004310 lactic acid Substances 0.000 abstract description 22
- 238000000034 method Methods 0.000 abstract description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 abstract description 4
- 238000012163 sequencing technique Methods 0.000 abstract description 4
- 241000269908 Platichthys flesus Species 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 238000012258 culturing Methods 0.000 abstract 2
- 108020001027 Ribosomal DNA Proteins 0.000 abstract 1
- 241000186660 Lactobacillus Species 0.000 description 27
- 229940039696 lactobacillus Drugs 0.000 description 27
- 239000003925 fat Substances 0.000 description 14
- 235000013618 yogurt Nutrition 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 10
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 9
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 9
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical group C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 9
- 229960002646 scopolamine Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 235000009200 high fat diet Nutrition 0.000 description 6
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 5
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 235000021001 fermented dairy product Nutrition 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 235000013322 soy milk Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000677540 Homo sapiens Acetyl-CoA carboxylase 2 Proteins 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000225 effect on diabetes Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 238000003044 randomized block design Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- 102100021641 Acetyl-CoA carboxylase 2 Human genes 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 238000010159 Duncan test Methods 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000011302 passive avoidance test Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Control | LG42 유산균 | |||
NDC | HDC | HD-LG42H | HD-LG42L | |
Serum(mg/㎗) | ||||
TC | 199.3±31.1c | 319.1±30.5b | 395.9±32.5a | 390.5±25.1a |
TG | 148.3±28.9b | 186.4±27.9a | 151.0±14.3b | 159.6±12.4b |
HDL-c | 113.3±24.8c | 168.7±33.3ab | 187.9±27.0a | 135±30.5bc |
HDL-c/TG | 56.8±0.8a | 24.0±1.1b | 47.5±0.8a | 34.7±1.2ab |
Liver(mg/g) | ||||
TC | 0.16±0.02 | 0.16±0.02 | 0.17±0.03 | 0.17±0.02 |
TG | 2.55±0.44b | 5.02±1.04a | 2.77±0.44b | 4.08±0.76ab |
Control | LG42 유산균 | |||
ND | HD | HD-LG42H | HD-LG42L | |
Serum ( nmol /100㎕) | ||||
NEC | 0.47±0.08b | 0.45±0.11b | 0.67±0.12a | 0.51±0.10b |
ASAC | 1.25±0.20a | 0.95±0.21b | 1.18±0.12a | 1.12±0.24a |
AIAC | 0.22±0.04b | 0.23±0.02b | 0.28±0.06a | 0.24±0.02ab |
Total carnitine | 1.88±0.24a | 1.54±0.17b | 2.04±0.25a | 1.92±0.24a |
Liver( nmol /100㎎ wet weight ) | ||||
NEC | 11.26±2.02a | 7.69±1.22b | 11.93±3.05a | 11.60±1.45a |
ASAC | 6.88±1.39a | 4.20±1.23b | 6.88±1.89a | 6.88±1.02a |
AIAC | 0.05±0.03 | 0.02±0.02 | 0.04±0.01 | 0.02±0.01 |
Total carnitine | 18.87±3.36a | 11.59±2.36b | 17.91±4.96a | 18.49±2.39a |
Claims (2)
- 체중과 지방 감소, 혈장 및 간 지질과 카르니틴 개선, 혈중 렙틴, 인슐린 농도 감소, 및 기억력 증진으로 이루어진 군에서 선택된 어느 하나의 용도로 락토바실러스 플란타룸 엔유씨 엘지 42 균주(기탁번호: KCCM 10940P).
- 락토바실러스 플란타룸 엔유씨 엘지 42 균주(기탁번호: KCCM 10940P)를 포함하는 식품 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080039216A KR101010914B1 (ko) | 2008-04-28 | 2008-04-28 | 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080039216A KR101010914B1 (ko) | 2008-04-28 | 2008-04-28 | 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090113478A true KR20090113478A (ko) | 2009-11-02 |
KR101010914B1 KR101010914B1 (ko) | 2011-01-26 |
Family
ID=41554802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080039216A KR101010914B1 (ko) | 2008-04-28 | 2008-04-28 | 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101010914B1 (ko) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101471033B1 (ko) * | 2013-10-21 | 2014-12-09 | 한국식품연구원 | 비만억제능이 우수한 신규한 웨이젤라 에스피 f22 균주 |
KR101476236B1 (ko) * | 2012-08-16 | 2014-12-24 | 경희대학교 산학협력단 | 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균 |
KR101500974B1 (ko) * | 2014-08-22 | 2015-03-13 | (주) 에이투젠 | 항염증 및 대사성질환 개선 효능을 가지는 락토바실러스 플란타룸 hac01 균주 및 이의 용도 |
KR101508586B1 (ko) * | 2013-10-21 | 2015-04-08 | 한국식품연구원 | 비만억제능이 우수한 신규한 엔테로코커스 휘칼리스 md366 균주 |
KR101512481B1 (ko) * | 2013-10-21 | 2015-04-16 | 한국식품연구원 | 비만억제능이 우수한 신규한 락토바실러스 플랜타룸 fh185 균주 |
KR101512482B1 (ko) * | 2013-10-21 | 2015-04-16 | 한국식품연구원 | 비만억제능이 우수한 신규한 락토바실러스 플랜타룸 q180 균주 |
KR102294456B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 람노서스 mg4502 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
KR102294445B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 파라카제이 mg4592 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
KR102294451B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 아시도필러스 mg4558 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
US11484557B2 (en) | 2018-08-31 | 2022-11-01 | Mediogen Co., Ltd. | Human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 strain having anti-obesity activity, and composition comprising same |
CN115651854A (zh) * | 2022-05-11 | 2023-01-31 | 珠海益何生物技术有限公司 | 一种植物乳杆菌yg06菌株及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210187044A1 (en) | 2016-05-24 | 2021-06-24 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of controlling blood sugar and use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0004124D0 (sv) * | 2000-11-10 | 2000-11-10 | Probi Ab | New use |
KR100686558B1 (ko) * | 2004-09-02 | 2007-02-23 | 씨제이 주식회사 | 체지방 저하 기능성 락토바실러스 플랜타륨와 이를 함유한 식품 |
JP5025930B2 (ja) | 2005-09-13 | 2012-09-12 | 株式会社桃屋 | ラクトバチルス・プランタラムの菌体を有効成分とする体脂肪率低減剤 |
-
2008
- 2008-04-28 KR KR1020080039216A patent/KR101010914B1/ko active IP Right Grant
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101476236B1 (ko) * | 2012-08-16 | 2014-12-24 | 경희대학교 산학협력단 | 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균 |
KR101471033B1 (ko) * | 2013-10-21 | 2014-12-09 | 한국식품연구원 | 비만억제능이 우수한 신규한 웨이젤라 에스피 f22 균주 |
KR101508586B1 (ko) * | 2013-10-21 | 2015-04-08 | 한국식품연구원 | 비만억제능이 우수한 신규한 엔테로코커스 휘칼리스 md366 균주 |
KR101512481B1 (ko) * | 2013-10-21 | 2015-04-16 | 한국식품연구원 | 비만억제능이 우수한 신규한 락토바실러스 플랜타룸 fh185 균주 |
KR101512482B1 (ko) * | 2013-10-21 | 2015-04-16 | 한국식품연구원 | 비만억제능이 우수한 신규한 락토바실러스 플랜타룸 q180 균주 |
KR101500974B1 (ko) * | 2014-08-22 | 2015-03-13 | (주) 에이투젠 | 항염증 및 대사성질환 개선 효능을 가지는 락토바실러스 플란타룸 hac01 균주 및 이의 용도 |
US11484557B2 (en) | 2018-08-31 | 2022-11-01 | Mediogen Co., Ltd. | Human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 strain having anti-obesity activity, and composition comprising same |
KR102294456B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 람노서스 mg4502 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
KR102294445B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 파라카제이 mg4592 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
KR102294451B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 아시도필러스 mg4558 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
CN115651854A (zh) * | 2022-05-11 | 2023-01-31 | 珠海益何生物技术有限公司 | 一种植物乳杆菌yg06菌株及其应用 |
Also Published As
Publication number | Publication date |
---|---|
KR101010914B1 (ko) | 2011-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101010914B1 (ko) | 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄 | |
JP6954563B2 (ja) | 代謝障害を処置するための低温殺菌アッカーマンシアの使用 | |
JP6608047B2 (ja) | 多様な機能性を有する新規乳酸菌およびその用途 | |
Das et al. | Traditional fermented foods with anti-aging effect: A concentric review | |
CN112930392B (zh) | 用于上呼吸道感染、压力、焦虑、记忆和认知功能障碍和衰老的益生菌 | |
CN112204129A (zh) | 植物乳杆菌kbl396菌株及其用途 | |
Liu et al. | The probiotic role of Lactobacillus plantarum in reducing risks associated with cardiovascular disease | |
JP7201837B2 (ja) | ロイコノストック・シトレウムwikim0104を含む肥満または脂肪肝疾患の予防、改善または治療用組成物 | |
KR102240196B1 (ko) | 신규한 락토바실러스 파라카세이 균주 | |
KR20150110378A (ko) | 후발효차 추출물을 포함하는 조성물 | |
KR101426275B1 (ko) | 지방합성 억제 및 지방산화 촉진에 의한 체지방 감소 효능을 갖는 5종의 유산균 복합균주를 유효성분으로 함유하는 조성물 | |
JP2019517992A (ja) | クリステンセネラ菌(Christensenella intestinihominis)およびその使用 | |
JP7414328B2 (ja) | ラクトバチルスアシドフィルスkbl409菌株およびその用途 | |
CN112955539A (zh) | 针对衰老、肌肉和骨骼、肠道、高脂血症、皮肤和大脑的益生菌菌株 | |
KR20190133639A (ko) | 락토바실러스 크리스파투스 kbl693 균주 및 그 용도 | |
JP6735338B2 (ja) | 腸内細菌のButyribacter intestiniおよびその使用 | |
KR20230005057A (ko) | 락토바실러스 속 균주 및 한약재를 포함하는 병용 요법을 이용한 항노화 조성물 | |
KR101280852B1 (ko) | 마(산약) 발효물 및 이의 제조 방법 | |
JP2020022488A (ja) | 多様な機能性を有する新規乳酸菌およびその用途 | |
KR101341263B1 (ko) | 프로바이오틱 락토바실루스 존소니이 아이디씨씨 9203을 이용한 발효울금의 제조방법 | |
KR101238836B1 (ko) | 혼합 유산균을 포함하는 비만 또는 비만 관련 질환 치료 또는 예방용 약제학적 조성물 또는 식품 조성물 | |
CN111867402A (zh) | 具有肝功能改善活性的蘑菇复合菌丝体组合物及其制造方法 | |
JP2007126399A (ja) | グルタチオン増加用組成物 | |
KR20170017176A (ko) | 장 내 유산균 증가용 조성물 및 이를 이용한 유산균 생산 방법 | |
KR100769299B1 (ko) | 알코올 분해능이 있는 유산균 및 그를 함유하는 유제품, 건강 기능성 식품 및 식품 첨가제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140106 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150112 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160119 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161230 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180105 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181123 Year of fee payment: 9 |